CD-001
Phase 1Small molecule
CD-001 is one of 47 small molecule programs targeting Head Neck Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
249 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Eloxatin
TevaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Camptosar
PfizerPhase 2
Tecentriq
RochePhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Trodelvy
GileadPhase 2
Erbitux
IImclone
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Lazcluze
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCD (Suzhou) Biopharma Co., Ltd.